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Attention Deficit Hyperactivity Disorder:  
Beyond the Practice Parameters
By Shelly Flynn, RN, MA, ARNP
Division of Pediatric Neurology, Behavior and Development
University of Iowa Children’s Hospital
Much has been written about 
the medical management of 
ADHD. I’ve chosen to discuss 
management beyond the prac-
tice parameters established 
by the American Academy of 
Pediatrics and the American 
Academy of Child and Ado-
lescent Psychiatry. This article 
will address what some of my 
toughest and easiest patients 
have taught me. 
Before medical treatment 
begins, the provider should 
feel confident that an accurate 
diagnosis of ADHD has been 
made and determine whether 
any co-morbid diagnoses, pre-
cautions, or contraindications 
to treatment exist. Stimulant 
medications are the drug of 
choice for most children and 
will significantly improve a 
child’s impulsivity, hyperactiv-
ity, and inattention. Stimulant 
medications available are 
either a methylphenidate or 
an amphetamine derivative. 
Both groups of medications 
are equally effective and have 
the same side effect profile. 
The stimulants can be grouped 
into short-acting (about 4 
hours), intermediate-acting 
(6-8 hours) and long acting 
(10-12 hours). I use them all, as 
there is value in each. Deter-
mining which medication(s), 
at what dose, will work best 
in each child without causing 
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Attention Deficit Hyperactivity Disorder
(continued from page 1)
(continues on page 7)
significant side effects, is the 
art of this practice, the fun of 
this practice, and a distressing 
part of this practice.
The medications are contrain-
dicated and/or to be used with 
caution in a few situations. 
The patient and family history, 
review of systems, and child’s 
physical exam usually provide 
the information needed to 
safely prescribe medications. 
Symptomatic heart disease, 
drug dependence, concurrent 
and very recent use of MAOIs, 
glaucoma, severe hyperten-
sion, and hyperthyroidism are 
contraindications. Patients 
with marked anxiety, mood 
disorders, impairing tic dis-
orders, epilepsy, history of 
substance abuse, and struc-
tural cardiac or cardiovascular 
conditions that may be com-
promised by increases in blood 
pressure or heart rate warrant 
caution when using stimulants. 
An EKG should be obtained 
if the patient’s history, fam-
ily history, or exam indicates 
increased risk of cardiovascular 
problems. Refer to cardiol-
ogy for clearance to safely 
take a stimulant medication if 
needed. I have patients with 
renal disease, hypertension, 
epilepsy, Tourette disorder, 
anxiety, depression, history of 
drug use, and cardiac disorders 
whose specialty physicians 
have cleared them for medical 
treatment of ADHD. In these 
cases the potential benefits of 
treatment outweighed the po-
tential risks. Treatment of these 
populations necessitates more 
frequent clinic visits, monitor-
ing of vital signs, and collabo-
ration with specialists.
Before beginning medica-
tion, get a good history of the 
child’s baseline sleep habits, 
eating habits, mood, growth 
history, personality, and any 
problems with headaches, 
stomachaches, and motor or 
vocal tics. The medications can 
cause problems with any of 
these. Dealing with the medi-
cation side effects can be the 
most challenging aspect of 
medical management. Appe-
tite suppression and sleep dis-
turbance, the most common 
side effects, can be profound. 
Baseline documentation allows 
the provider to clearly identify 
whether prescribed medica-
tions create new problems 
for the child. ADHD is chronic. 
Kids deserve to feel good and 
should not be chronically 
bothered by a medication they 
take daily. Switch medications 
if side effects interfere with the 
child’s quality of life.
The goal is to find the right 
medication(s) and dosage(s) 
that promote success by ob-
taining reasonable control of 
the child’s symptoms without 
causing significant side effects. 
References to specific medica-
tions are included in the ADHD 
Medication Chart (pages 5 and 
6). The chart is not all-inclusive, 
but does list primary medica-
tions on a single page. It does 
not include the tricyclic anti-
depressants, as I refer to child 
psychiatry for that treatment. 
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Early Identification
of  Learning Disabilities
Tammy L. Wilgenbusch, PhD
Pediatric Psychologist, University of Iowa Children’s Hospital
Rather than waiting for indica-
tions of trouble to become ma-
jor problems, the field of learn-
ing disabilities today focuses 
on early identification and 
prevention. In the 1970’s and 
1980’s, learning disabilities (LD) 
were defined by the discrep-
ancy between achievement 
and intellectual ability. This 
led to a stringent use of test 
scores, with arbitrary cut-off 
points determining diagnoses. 
Focusing only on a discrep-
ancy often results in delayed 
treatment as these discrepan-
cies often don’t show up until 
mid-elementary school, past 
the optimal time for adequate 
development of skills required 
for reading and math.
Recently, the focus has shifted 
to identifying and providing 
early treatment and prevention 
in younger children who may 
be at risk for LD. In younger 
children, neurocognitive skills 
and learning patterns are still 
developing, leading to great 
variability in skills. This makes 
testing somewhat difficult. For 
children younger than 6 or 7 
years old, screening for risk of 
learning difficulties and global 
delays is most reliable. There-
fore, evaluation of LD at this 
age should focus on specific 
prerequisite skills and not nec-
essarily a full neuropsychologi-
cal evaluation.
Most research on LD in chil-
dren in early elementary has 
been on reading. New research 
indicates that the best time 
to screen and start treat-
ment to prevent reading LD 
is in kindergarten or early 1st 
grade. In addition to screen-
ing at school, it is helpful when 
primary care physicians also 
screen these children for learn-
ing difficulties, enabling par-
ents to use early intervention 
resources. 
Specific skills in kindergarten 
and 1st grade that are pre-
dictive of later reading skills 
include: phonological aware-
ness (knowledge of the audi-
tory patterns and structure 
of language); graphonomic 
knowledge (knowledge of the 
relationship between printed 
letter and sounds); letter 
knowledge; picture naming 
and vocabulary; rapid auto-
matic naming; and phono-
logical memory. Tasks that can 
help assess these skills include 
a child’s ability to identify 
rhymes, tap the number of 
syllables or phonemes heard in 
a spoken word, blend sounds 
together to generate a word, 
and delete a sound to form a 
new word. In addition, basic 
alphabet identification and 
rapid naming of letters can be 
a good screen for these diffi-
culties.
Children with difficulties in the 
prerequisite skills of reading 
are at risk for developing read-
ing disabilities as they prog-
ress through school and need 
additional, specific instruction 
in kindergarten and 1st grade. 
There are three components of 
instruction for children at risk 
for reading disabilities. First, 
instruction needs to be very 
systematic and explicit, typi-
cally using a phonics-based 
(continues on page 4)
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approach. Second, instruction 
needs to be intensive, with 
many learning opportunities 
throughout the day. Third, 
instruction should be sup-
portive and include positive 
feedback, encouragement, and 
the scaffolding of skills. For 
these younger children with 
LD, school is the best refer-
ral source. Parents seeking 
additional support may wish 
to obtain private testing and 
screening by a psychologist.
In addition to achievement-
based LD, children may have 
difficulties not related to a cog-
nitive delay that interfere with 
their overall classroom learn-
ing and performance. For ex-
ample, children with attention 
or memory problems may have 
difficulty following directions 
at school, leading to more 
global academic concerns. 
When determining whether 
mid-elementary to high school 
students are dealing with 
learning difficulties, physicians 
can ask questions regarding 
problems with work comple-
tion, not turning in assign-
ments, inability to do well on 
timed tests, difficulty following 
directions, poor reading fluen-
cy, and difficulty with compre-
hension or test performance. 
If children are having these 
types of difficulties, regardless 
of achievement scores, further 
neuropsychological testing can 
be helpful to identify underly-
ing strengths and weakness 
that can help in the develop-
ment of intervention and strat-
egies to help improve overall 
academic success.
While not all children need 
neuropsychological testing, 
testing is warranted when chil-
dren do not respond to early 
prevention or basic instruction 
to determine whether there is 
an underlying neurocognitive-
based learning difficulty. This 
testing should focus on a 
variety of cognitive skills and 
identify patterns of strength 
and weakness. In the Division 
of Pediatric Psychology at the 
University of Iowa Children’s 
Hospital, neuropsychological 
testing focuses on the skills 
of verbal comprehension, 
expressive language, visual-
spatial-motor skills, memory, 
attention, and processing 
speed. The goal is to gain an 
understanding of the child’s 
strengths and weaknesses 
so that specific accommoda-
tions can be recommended to 
parents and teachers. Neuro-
psychological testing is valu-
able because it goes beyond 
academic performance, pro-
viding specific information 
that can guide intervention, 
rather than focusing strictly on 
overall scores.
In summary, it is important to 
screen young children, start-
ing in kindergarten, for specific 
prerequisite skills that lead 
to adequate development of 
academic skills, particularly 
reading. Neuropsychologi-
cal testing at this age can be 
helpful for identifying skills 
that should be monitored or 
for global delays, but specific 
neurocognitive LD are difficult 
to identify due to the wide 
variability of children’s be-
havior and skills. After a child 
reaches 6 or 7 years of age, or 
if more global or broad learn-
ing concerns are noted, referral 
for neuropsychological testing 
may be warranted to assist 
with the development of spe-
cific interventions and school 
accommodations for the child.
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Orthostatic hypotension, palpitations, bradycardia, depression, dizziness, fatigue, headache, som
nolence, anorexia, 
constipation, acid indigestion, liver toxicity.  
Avoid with significant liver, kidney, or cerebrovascular disease.  Avoid abrupt withdrawal (to avoid rebound 
hypertension).  
Start with 0.5 m
g in the evening and increase by 0.5 m
g every 7 
days as indicated to no m
ore than 1m




dose of 4 m
g. Divided into BID to TID dosing. 
Don’t skip doses (to avoid rebound hypertension). 
Need to taper off. 
Helpful for sleep disturbance, tics, m
odulating m









2  – Adrenergic 
agonist
Tablets
1,  2, 3, 
and 4 m
g
Orthostatic hypotension, palpitations, bradycardia, depression, dizziness, fatigue, headache, som
nolence, anorexia, 
constipation, acid indigestion, liver toxicity.  
Avoid with significant liver,  kidney, or cerebrovascular disease.  Avoid abrupt withdrawal (to avoid rebound 
hypertension).  
Start with 1 m
g/day in the evening and increase by 1 m
g  every 
7 days as indicated. Once a day dosing. Daily dose range 1-4 m
g/
day with a m
axim
um
 daily dose of 4 m
g.  
Don’t skip doses (to avoid rebound hypertension). 
Need to taper off.  
Helpful for sleep disturbance, tics, m
odulating m














Dizziness, sedation, confusion, nausea, vom
iting, constipation, local reaction to patch, hypotension, weakness, 
som
nolence, im
potence, pancreatitis, agranulocytosis, electrolyte im
balance. 
Avoid abrupt withdrawal (to avoid rebound hypertension). 
Contraindication: 1)allergy, 2)conduction disturbances, 3)chronic renal failure, 4)severe coronary insuffi
ciency, 5)
cerebrovascular disease
(Not approved by the FDA for ADHD)
Start with a dose of .025-.05 m
g/day in evening. Titrate in 
0.05m
g increm
ents no faster than every 7 days. Given in divided 
doses 2-4 tim
es per day. Daily dose range 0.1-0.3 m
g/day. Do not 
skip doses (to avoid rebound hypertension).
M
ay not see effects for 4-6 weeks.
Need to taper off. 
Helpful for sleep disturbance, tics, m
odulating m


















Decreased appetite, weight loss, nausea, vom
iting,  (take with food), sedation, m
ood swings, and lightheadedness.
 Use cautiously in patients with hypertension, hypotension, tachycardia, cardiovascular or cerebrovascular disease 
(m
onitor vitals), hepatic or renal insuffi
ciencies (can increase blood pressure and heart rate), and urinary retention.  
Use cautiously in patients with poor m
etabolizer CYP2D6 phenotype or aggressive behaviors.
 Do not use if currently using, or have used within 2 weeks any M
AOI. Do not use with narrow angle glaucom
a. Not 
indicated in patients with a seizure disorder or with a current or previous diagnosis of bulim




arning: Increased risk of suicidal ideation in short-term
 studies in children or adolescents with 
Attention-Deficit/Hyperactivity Disorder (ADHD). M
onitor patients closely for suicidality (suicidal thinking and 
behavior), clinical worsening, or unusual changes in behavior.
Initial dose 0.5 m
g/kg given as single dose in AM
. (Increase up to 
1.2 m
g/kg after 4-7 days).
 Targeted clinical dose is approxim
ately 1.2 m








ust be used each day. If the higher doses are 







oxetine, continue the 
stim




er:  This chart is not intended to serve as a totally com
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For an electronic version of the 
chart, visit http://iowaepsdt.
org/EPSDTNews/index.htm. 
Always start medication with 
the lowest dose available, in a 
formulation that is easy for the 
child to take (sprinkles, chew-
able, patch, tablet, or powder 
mixed with juice), and of a 
duration in which you want the 
symptoms controlled. These 
issues are more important than 
whether you choose a methyl-
phenidate or an amphetamine 
as there is no way to predict 
which medication will work 
best in each child, without 
causing significant side effects.  
Next, assess the response to 
the medication and evaluate 
for side effects. Increase to 
the next available strength if 
symptoms are still significant, 
as long as there are not signifi-
cant side effects. Each of the 
stimulant medications has an 
FDA recommended maximum 
dose. Some providers increase 
beyond those dosages with 
discretion. One might as-
sume it is best to choose the 
longest acting (10- to12-hour 
long) medication for all kids. 
The very young (4 to 7 years) 
though, have many fewer side 
effects on the intermediate-
acting medications (6- to 
8-hour long) than the longer 
acting medications. Combina-
tion therapy is useful in obtain-
ing control of symptoms with 
few to no side effects. A little 
of this and that is less likely to 
cause side effects than a lot of 
this and none of that.  
In addition to stimulants, 
guanfacine, Intuniv, clonidine, 
Strattera, melatonin, and 
cyproheptadine can be help-
ful additional medications for 
better symptom control and 
treatment of side effects, or for 
baseline problems with sleep, 
tics, anger, and poor appetite. 
It can be helpful for parents 
to fill out tools such as the 
Vanderbilt Assessment Scale 
or Conners Rating Scale. I ask 
parents to call our nurses with 
an update within one to three 
weeks after starting medica-
tion, sooner if there are worri-
some side effects. I adjust med-
ication over the telephone as 
needed and see the child again 
within one to three months, 
and then two to four times per 
year. Excellent secretarial and 
nursing staff members assist 
parents by phone with fine 
tuning medications in a timely 
manner. 
Educational accommodations, 
behavioral interventions, and 
support from a multitude of 
health and community provid-
ers combine to create the best 
treatment plan for children 
with ADHD. In the best of situ-
ations, these children require 
a lot of energy: remember 
to support the parents. As a 
provider, watching and help-
ing these kids achieve success 
is worth all the energy they 
require. 
Attention Deficit Hyperactivity Disorder
(continued from page 1)
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The  EPSDT Care for Kids Newsletter  is published 
three times a year, in print and online, as a joint effort 
of the Iowa Prevention of Disabilities Policy Council, 
the Iowa Department of Human Services, the Iowa 
Department of Public Health, and the Center for 
Disabilities and Development, which is nationally 
designated as Iowa’s University Center for Excellence 
on Disabilities. The goal of this newsletter is to inform 
Iowa health care professionals about the EPSDT Care 
for Kids program, to encourage them to make use of 
this important resource, and to provide them with 
information about a wide range of developments 
in the field of health care. 
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